Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Other Accumulated Expenses: 2018-2020

  • Outlook Therapeutics' Other Accumulated Expenses was N/A to $2.6 million in Q2 2020 from the same period last year, while for Jun 2020 it was $2.6 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2019, which is 58.85% up from last year.
  • Outlook Therapeutics' Other Accumulated Expenses amounted to $2.6 million in Q2 2020, which was up 17.14% from $2.3 million recorded in Q1 2020.
  • In the past 5 years, Outlook Therapeutics' Other Accumulated Expenses ranged from a high of $2.8 million in Q4 2019 and a low of $1.1 million during Q3 2018.
  • For the 3-year period, Outlook Therapeutics' Other Accumulated Expenses averaged around $2.1 million, with its median value being $2.3 million (2020).
  • Data for Outlook Therapeutics' Other Accumulated Expenses shows a peak YoY skyrocketed of 58.85% (in 2019) over the last 5 years.
  • Over the past 3 years, Outlook Therapeutics' Other Accumulated Expenses (Quarterly) stood at $1.1 million in 2018, then surged by 58.85% to $2.8 million in 2019, then reached $2.6 million in 2020.
  • Its Other Accumulated Expenses stands at $2.6 million for Q2 2020, versus $2.3 million for Q1 2020 and $2.8 million for Q4 2019.